Impact of Polymorphism in Base Excision Repair and Nucleotide Excision Repair Genes and Risk of Cervical Cancer: A Case-Control Study.
Case-Control Studies
DNA Repair
/ genetics
DNA-Binding Proteins
/ genetics
Female
Genetic Predisposition to Disease
Humans
India
Polymorphism, Single Nucleotide
Uterine Cervical Neoplasms
/ genetics
X-ray Repair Cross Complementing Protein 1
/ genetics
Xeroderma Pigmentosum Group D Protein
/ genetics
BER
Cervical cancer
NER
PCR-RFLP
SNP
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
received:
21
10
2021
entrez:
29
4
2022
pubmed:
30
4
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Last few years, several studies all over the world revealed the association of DNA repair genes with risk of developing different type of cancers, but were ambiguous to support the evidences in case of cervical cancer risk. These differences in earlier studies directed us to study the association of polymorphisms of BER genes (XRCC1, hOGG1, XPC) and NER genes (XPC, XPD) with cervical cancer susceptibility in the women of rural population of Maharashtra. The genetic polymorphism in BER and NER pathway genes was studied by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method using DNA isolated from intravenous blood samples of patients and normal controls. The study included 400 clinically confirmed cervical cancer patients and 400 healthy women from a tertiary care hospital (Krishna Hospital and Medical Research Centre) of south-western Maharashtra. The association of polymorphisms was confirmed by Odds ratio (OR) with 95% confidence interval. The single nucleotide polymorphism (SNP) of BER genes including XRCC1, hOGG1 and APE1 were analyzed and the results were noted that 27466AA (OR=4.88; 95% CI: 3.61- 6.60; p<0.0001) and 28152AA (OR=2.89; 95% CI: 1.57- 5.31; p=0.0005) genotypes of XRCC1 (rs25489, rs25487) were significantly associated with cervical cancer risk. The 1245GG genotype of hOGG1 (rs1052133) (OR=45.30; 95% CI: 3.76- 7.46; p=0.001) also showed significant correlation, whereas 2197GG genotype of APE1 (rs1130409) gene showed negative association with cervical carcinogenesis (OR=0.59; 95% CI: 0.35- 0.97; p=0.005). Similarly when we studied SNPs of NER genes including XPC and XPD genes, 21151TT genotype of XPC (rs 2228000) was positively associated with cervical cancer development and 23591AA genotype of XPD (rs1799793) showed negative association (OR=0.34; 95% CI: 0.17- 0.64; p=0.001). The findings from this study supported that rs25489, rs25487SNPs of XRCC1, rs1052133 of hOGG1 and rs2228000 of XPC may increase cervical cancer risk, whereas rs1130409 SNP of APE1 and rs1799793 SNP of XPD gene lower the risk of cervical cancer in the studied population.
Sections du résumé
BACKGROUND
BACKGROUND
Last few years, several studies all over the world revealed the association of DNA repair genes with risk of developing different type of cancers, but were ambiguous to support the evidences in case of cervical cancer risk. These differences in earlier studies directed us to study the association of polymorphisms of BER genes (XRCC1, hOGG1, XPC) and NER genes (XPC, XPD) with cervical cancer susceptibility in the women of rural population of Maharashtra.
MATERIALS AND METHODS
METHODS
The genetic polymorphism in BER and NER pathway genes was studied by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method using DNA isolated from intravenous blood samples of patients and normal controls. The study included 400 clinically confirmed cervical cancer patients and 400 healthy women from a tertiary care hospital (Krishna Hospital and Medical Research Centre) of south-western Maharashtra. The association of polymorphisms was confirmed by Odds ratio (OR) with 95% confidence interval.
RESULTS
RESULTS
The single nucleotide polymorphism (SNP) of BER genes including XRCC1, hOGG1 and APE1 were analyzed and the results were noted that 27466AA (OR=4.88; 95% CI: 3.61- 6.60; p<0.0001) and 28152AA (OR=2.89; 95% CI: 1.57- 5.31; p=0.0005) genotypes of XRCC1 (rs25489, rs25487) were significantly associated with cervical cancer risk. The 1245GG genotype of hOGG1 (rs1052133) (OR=45.30; 95% CI: 3.76- 7.46; p=0.001) also showed significant correlation, whereas 2197GG genotype of APE1 (rs1130409) gene showed negative association with cervical carcinogenesis (OR=0.59; 95% CI: 0.35- 0.97; p=0.005). Similarly when we studied SNPs of NER genes including XPC and XPD genes, 21151TT genotype of XPC (rs 2228000) was positively associated with cervical cancer development and 23591AA genotype of XPD (rs1799793) showed negative association (OR=0.34; 95% CI: 0.17- 0.64; p=0.001).
CONCLUSION
CONCLUSIONS
The findings from this study supported that rs25489, rs25487SNPs of XRCC1, rs1052133 of hOGG1 and rs2228000 of XPC may increase cervical cancer risk, whereas rs1130409 SNP of APE1 and rs1799793 SNP of XPD gene lower the risk of cervical cancer in the studied population.
Identifiants
pubmed: 35485688
doi: 10.31557/APJCP.2022.23.4.1291
pmc: PMC9375594
pii:
doi:
Substances chimiques
DNA-Binding Proteins
0
X-ray Repair Cross Complementing Protein 1
0
XRCC1 protein, human
0
Xeroderma Pigmentosum Group D Protein
EC 3.6.4.12
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1291-1300Références
DNA Repair (Amst). 2016 Nov;47:30-41
pubmed: 27707541
Heliyon. 2021 Jan 09;7(1):e05919
pubmed: 33490679
J BUON. 2020 Jan-Feb;25(1):574-581
pubmed: 32277685
Oncotarget. 2016 Oct 4;7(40):66061-66068
pubmed: 27603140
Indian J Med Res. 2012;135:64-71
pubmed: 22382185
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211033060
pubmed: 34278875
Med Oncol. 2014 Aug;31(8):67
pubmed: 24958516
PLoS One. 2014 Apr 15;9(4):e93937
pubmed: 24736739
BMC Med Genet. 2018 May 2;19(1):67
pubmed: 29720094
Asian Pac J Cancer Prev. 2020 Jul 01;21(7):2061-2065
pubmed: 32711433
Oncotarget. 2017 Jan 10;8(2):2249-2260
pubmed: 27903984
Indian J Cancer. 2020 Apr-Jun;57(2):187-189
pubmed: 32167073
Oncol Lett. 2011 Jan;2(1):155-159
pubmed: 22870145
Genet Test Mol Biomarkers. 2019 Feb;23(2):138-144
pubmed: 30648893
Clin Exp Gastroenterol. 2020 Mar 16;13:73-86
pubmed: 32214837
Tumour Biol. 2016 Jul;37(7):9139-49
pubmed: 26768611
World J Gastroenterol. 2015 Apr 28;21(16):5081-9
pubmed: 25945024
Jpn J Clin Oncol. 2019 Jan 01;49(1):77-86
pubmed: 30407555
Medicine (Baltimore). 2020 May 22;99(21):e20299
pubmed: 32481313
Br J Biomed Sci. 2019 Jul;76(3):117-121
pubmed: 30870085
Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033821990046
pubmed: 33517857
J Clin Diagn Res. 2014 Nov;8(11):CC17-20
pubmed: 25584213
Anal Cell Pathol (Amst). 2018 Aug 26;2018:3806514
pubmed: 30225185
Data Brief. 2016 Nov 26;10:11-13
pubmed: 27942558
Eur J Cancer Prev. 2016 May;25(3):224-31
pubmed: 25812040
Technol Cancer Res Treat. 2017 Dec;16(6):692-704
pubmed: 28797198
J Cancer Res Ther. 2018 Apr-Jun;14(3):651-657
pubmed: 29893334
Onco Targets Ther. 2016 Sep 07;9:5513-9
pubmed: 27660469